The state of Connecticut currently has 65 active clinical trials seeking participants for Lung Cancer research studies. These trials are conducted in various cities, including New Haven, Hartford, Farmington and Stamford.
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Danbury Hospital, Danbury, Connecticut +24 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
Recruiting
The purpose of this trial is to test a deescalated 3-fraction stereotactic body radiotherapy (SBRT) regimen to 45 Gray (Gy) in 3 fractions for centrally located thoracic tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2024
Locations: Smilow Cancer Hospital, New Haven, Connecticut
Conditions: Non-small Cell Lung Cancer
The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
Recruiting
This is a phase 2 study to investigate NC318 alone or in combination with Pembrolizumab in patients with advanced non-small cell lung cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Advanced Non-small Cell Lung Cancer
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Recruiting
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/04/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
Recruiting
This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
03/28/2024
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: Lung Cancer